Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma by Rodrigues, P.C. et al.
Oncotarget74736www.impactjournals.com/oncotarget
Fascin promotes migration and invasion and is a prognostic 
marker for oral squamous cell carcinoma
Priscila Campioni Rodrigues1,2, Iris Sawazaki-Calone3, Carine Ervolino de Oliveira1, 
Carolina Carneiro Soares Macedo1, Mauricio Rocha Dourado1,2, Nilva K. Cervigne1,10, 
Marcia Costa Miguel4, Andreia Ferreira do Carmo1,4, Daniel W. Lambert5, Edgard 
Graner1, Sabrina Daniela da Silva6,7, Moulay A. Alaoui-Jamali6,7, Adriana Franco 
Paes Leme8, Tuula A. Salo1,2,9 and Ricardo D. Coletta1
1Department of Oral Diagnosis, School of Dentistry, University of Campinas, Piracicaba, SP, Brazil
2Unit of Cancer Research and Translational Medicine, Faculty of Medicine and Medical Research Center Oulu, Oulu University 
Hospital, University of Oulu, Oulu, Finland
3Oral Pathology and Oral Medicine, Dentistry School, Western Paraná State University, Cascavel, PR, Brazil
4Department of Dentistry, Federal University of Rio Grande do Norte, Natal, RN, Brazil
5Integrated Biosciences, School of Clinical Dentistry and Sheffield Cancer Centre, University of Sheffield, Sheffield, United 
Kingdom
6Departments of Medicine, Oncology, Pharmacology and Therapeutics, Segal Cancer Centre and Lady Davis Institute for 
Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada
7Otolaryngology-Head and Neck Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
8Brazilian Biosciences National Laboratory-CNPEM, Campinas, SP, Brazil
9Institute of Oral and Maxillofacial Disease, University of Helsinki, and HUSLAB, Department of Pathology, Helsinki University 
Hospital, Helsinki, Finland
10Current/Present address: Clinical Department, Faculty of Medicine of Jundiai, Jundiai, SP, Brazil
Correspondence to: Priscila Campioni Rodrigues, email: priscilacampioni@gmail.com
Keywords: fascin, plectin, oral squamous cell carcinoma, migration and invasion, prognosis
Received: April 07, 2017    Accepted: July 12, 2017    Published: August 19, 2017
Copyright: Rodrigues et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Oral squamous cell carcinoma (OSCC) prognosis is related to clinical stage and 
histological grade. However, this stratification needs to be refined. We conducted a 
comparative proteome study in microdissected samples from normal oral mucosa 
and OSCC to identify biomarkers for malignancy. Fascin and plectin were identified 
as differently expressed and both are implicated in several malignancies, but the 
clinical impacts of aberrant fascin and plectin expression in OSCCs remains largely 
unknown. Immunohistochemistry and real-time quantitative PCR were carried out 
in ex vivo OSCC samples and cell lines. A loss-of-function strategy using shRNA 
targeting fascin was employed to investigate in vitro and in vivo the fascin role on 
oral tumorigenesis. Transfections of microRNA mimics were performed to determine 
whether the fascin overexpression is regulated by miR-138 and miR-145. We found 
that fascin and plectin are frequently upregulated in OSCC samples and cell lines, 
but only fascin overexpression is an independent unfavorable prognostic indicator 
of disease-specific survival. In combination with advanced T stage, high fascin level 
is also an independent factor of disease-free survival. Knockdown of fascin in OSCC 
cells promoted cell adhesion and inhibited migration, invasion and EMT, and forced 
expression of miR-138 in OSCC cells significantly decreased the expression of fascin. 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 43), pp: 74736-74754
                                                               Research Paper
Oncotarget74737www.impactjournals.com/oncotarget
In addition, fascin downregulation leads to reduced filopodia formation and decrease 
on paxillin expression. The subcutaneous xenograft model showed that tumors 
formed in the presence of low levels of fascin were significantly smaller compared 
to those formed with high fascin levels. Collectively, our findings suggest that fascin 
expression correlates with disease progression and may serve as a prognostic marker 
and therapeutic target for patients with OSCC.
INTRODUCTION
Oral squamous cell carcinoma (OSCC) is the 
eleventh most commonly diagnosed cancer worldwide, 
accounting for 300,000 new cases and 145,000 deaths 
per year [1]. The most relevant OSCC prognostic 
factor is clinical staging of the disease based on TNM 
classification (tumor size, lymph node spread and distant 
metastasis), however, the behavior of some OSCCs are 
uncertain [2, 3]. Besides, histological scoring systems 
are constantly revised, and in numerous instances 
new scoring systems have shown an important role in 
prognostication of patients with OSCC [4, 5]. Surgery 
remains the mainstay of curative treatment, while the 
response to chemo and radiotherapy is limited. Owing to 
late diagnosis and frequent development of locoregional 
recurrences and second primary tumors, mortality rates 
are 50% over 5 years and have remained unchanged over 
recent decades [6]. At advanced stage, OSCC has an 
extremely poor prognosis. Therefore, the identification 
of novel biomarkers for early detection, post-therapeutic 
monitoring and to facilitate development of novel 
therapeutic approaches is of great importance.
Fascin and plectin are cytoskeleton-binding 
proteins associated with cell motility in both normal and 
neoplastic conditions [7]. Fascin bundles actin filaments 
within dynamic cellular structures such as microspikes, 
stress fibers and membrane ruffles [8]. The expression 
of fascin is low or absent in adult epithelial cells, but 
its overexpression in tumors is associated with poor 
prognosis [9]. Functional studies revealed that fascin has 
the ability to promote migration and invasion of carcinoma 
cells in vitro [10], and its expression is associated with 
increased invasive and metastatic potential in mouse 
xenograft tumor models [11]. In OSCCs, fascin expression 
level was associated with aggressiveness [12, 13] and an 
in vitro study showed that fascin regulates epithelial-
mesenchymal transition (EMT) and invasion of OSCC 
cells [14]. Plectin is important to maintain intracellular 
architectures and the normal cellular morphology after 
binding to cytoskeletal proteins (reviewed in [15]). Plectin 
also mediates the polymerization of fibronectin fibrils 
while fibrillar adhesions occur [16], and participates 
in regulation of cell migration and invasion through 
activation of ERK1/2 kinase [7, 17]. Although few studies 
have demonstrated overexpression in cancer cells, the 
participation and the mechanisms of action and regulation 
of plectin in cancer remain elusive. The study by Katada 
and collaborators [17] showed that plectin levels are 
correlated with proliferation, migration, invasion and poor 
prognosis in head and neck squamous cell carcinomas. 
With the exception of this study, little has been uncovered 
regarding the biological mechanisms related to plectin 
in oral cancer. Although the emerging literature suggests 
the clinical importance of fascin and plectin on human 
cancers as potential prognostic markers or therapeutic 
targets, there are still very little molecular details defining 
the mechanisms of action of those proteins in the control 
of oral tumorigenesis.
Laser-capture microdissection associated with mass 
spectrometry-based proteomics analysis (LC-MS/MS) 
conducted by our group revealed that fascin and plectin are 
overexpressed in OSCC tissues in comparison with oral 
healthy mucosas [18]. In the present study, we examined 
the expression levels of fascin and plectin in OSCC 
clinical samples and cell lines to determine the prognostic 
impact of those proteins for OSCC patients. Moreover, 
we assessed whether fascin knockdown influences OSCC 
cell proliferation, adhesion, migration, invasion, EMT and 
filopodia formation in vitro. The influence of modulating 
fascin expression in vivo was examined using OSCC 
tumor formation and cervical lymph node metastasis 
models. Furthermore, to understand the molecular 
mechanism through which fascin is overexpressed, the 
regulation of fascin expression by miR-138 and miR-
145 was investigated in OSCC cell lines and clinical 
specimens.
RESULTS
Fascin and plectin are overexpressed in OSCC 
tissues and cell lines
Firstly, fascin and plectin expression levels were 
validated in the same cohort used in the previously 
reported LC-MS/MS analyses [18] to confirm that 
both proteins are overexpressed in OSCCs compared 
to normal tissues. Immunostaining for both fascin and 
plectin showed a cytoplasmic pattern (Figure 1). Normal 
epithelium revealed weak or partly moderate staining 
restricted to the lower layers for both fascin (Figure 1A) 
and plectin (Figure 1D), whereas tumor cells showed 
variable distribution and intensity of fascin (Figure 1B) 
and plectin (Figure 1E). Immunopositivity for fascin 
was also found in the endothelial cells, and plectin 
immunoreactivity was detected in some inflammatory cells 
of the stroma. Analysis of intensity of staining showed that 
both fascin (p<0.0001, Figure 1C) and plectin (p<0.0001, 
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Figure 1F) were significantly more abundantly expressed 
in OSCCs than in control mucosas.
The expression of fascin and plectin was analyzed 
by qPCR in fresh samples from normal oral mucosa and 
OSCC. In this experiment, we pooled 11 normal oral 
mucosa and used these as a reference. The variation on 
fascin and plectin expression levels was small among 
control samples. A significantly higher level of fascin 
mRNA was observed in the group of fresh tumors in 
comparison to reference pool (p<0.01, Figure 2A) and 
one sample showed fascin level similar to normal control. 
The mRNA levels of plectin were also significantly higher 
in the group of OSCC samples (p<0.05, Figure 2C), but 
2 tumor samples showed lower plectin levels than the 
normal mucosa reference pool. The levels of fascin mRNA 
were significantly higher in the OSCC cell lines SCC-4 
(p<0.0001), SCC-9 (p<0.001), SCC-15 (p<0.0001), SCC-
25 (p<0.0001), SCC-9 ZsGreen LN-1 (p<0.01) and HSC-3 
(p<0.001) compared with the spontaneously immortalized, 
but not transformed epithelial cell line HGK (Figure 2B). 
Similarly, plectin was significantly more abundantly 
expressed in the SCC-4 (p<0.0001), SCC-9 (p<0.05), 
SCC-15 (p<0.0001), SCC-25 (p<0.0001), SCC-9 ZsGreen 
LN-1 (p<0.001) and HSC-3 (p<0.01) than in the HGK 
(Figure 2D).
The fascin protein levels were significantly higher 
in OSCCs than in fibrous hyperplasias (p<0.0001) and 
in dysplasias, independent of the grade (p<0.001; Figure 
3A and 3B). Interesting, the expression of fascin in oral 
dysplasias was not limited to the lower layers of the 
epithelium (Figure 3A). Fascin was also significantly 
upregulated in the dysplasia samples when compared 
with fibrous hyperplasias (p<0.001; Figure 3B). The 
levels of plectin were significantly higher in OSCCs than 
in fibrous hyperplasias and dysplasias (p<0.0001; Figure 
3C and 3D). However, no differences between fibrous 
hyperplasia and dysplasias were observed (Figure 3D). 
Thus, these data demonstrate that both fascin and plectin 
are frequently upregulated in OSCC tissues and cell lines.
Expression of fascin is associated with survival of 
patients with OSCC
To evaluate the correlation between protein levels of 
fascin and plectin and clinicopathological characteristics, 
the patients of OSCC cohort 1 were divided into low 
and high expression subgroups with the median value 
as the cutoff. As shown in Table 1, the upregulation of 
fascin in OSCC tissues was not correlated with the 
clinicopathological features of tumors, while a significant 
correlation between plectin levels and involvement of the 
surgical margin was found (p=0.04).
We next assessed the association between expression 
of fascin and plectin and clinical prognosis of OSCC 
patients (cohort 1). The outcomes were categorized as 
disease-specific survival, time from treatment initiation 
until death due to cancer or last known date alive, and 
disease-free survival, time from treatment initiation 
until diagnosis of the first recurrence (local, regional or 
distant) or last follow-up information for those without 
Figure 1: Higher expression levels of fascin and plectin in OSCCs. Representative immunohistochemical expression patterns 
of fascin and plectin in normal oral mucosa and OSCC specimens are shown. Both fascin (A) and plectin (D) expression were limited to 
the cytoplasm of the basal and suprabasal layers of the normal oral tissue. OSCC tumor cells showed variable distribution and intensity of 
fascin (B) and plectin (E). Quantification of the positive expression of both fascin (C) and plectin (F) in the ten original pairs of samples 
used in the LC–MS/MS revealed a significantly higher expression in OSCC cells compared with normal oral mucosa cells *p<0.0001.
Oncotarget74739www.impactjournals.com/oncotarget
recurrence. Patients with higher fascin expression had 
significantly poorer disease-specific survival (p<0.001) 
rate than those with lower fascin expression (Figure 4A). 
High fascin immunoreactivity showed a tendency towards 
association with shortened disease-free survival (Figure 
4B). Recurrence was diagnosed in 48.8% of patients 
with strong positivity for fascin after 5-year follow up 
compared with 28.4% for those with low fascin expression 
(p=0.09; Figure 4B). For plectin, survival analyses 
based on univariate log-rank test revealed no significant 
association with both disease-specific survival (Figure 
4C) and disease-free survival (Figure 4D). The univariate 
analysis for disease-specific survival and disease-free 
survival of the OSCC cohort is provided as Supplementary 
Materials (Supplementary Figures 1 and 2).
Multivariate Cox regression analyses confirmed that 
fascin expression level, together with patient age, size of 
the primary tumor (T stage) and regional metastasis at 
diagnosis (N stage), was an independent risk factor for 
disease-specific survival in this cohort (Table 2). A HR 
of 2.86 (95% CI: 1.34-6.12, p=0.007) was found for high 
expression of fascin in relation to low expression.
In order to strength the prognostic information of 
these independent factors, we combined fascin expression 
levels with age, T stage and N stage and performed 
univariate and multivariate survival analysis. There were 
significant associations of combinations of fascin levels 
and T stage in both DSS and DFS and of fascin levels and 
N stage in DSS (Table 3). In all combinations, the survival 
curves suggested a largely improved discriminatory 
ability. Interestingly, DFS was not significantly associated 
with fascin level alone, but when combined with T stage, 
a significant association was observed (HR: 4.17, 95% CI: 
1.39-12.43, p=0.01), revealing an independent prognostic 
discrimination.
Figure 2: Fascin and plectin are overexpressed in OSCCs and OSCC-derived cell lines. Total RNA from fresh samples and 
cell lines were converted in cDNA and subjected to qPCR. (A) In the fresh samples, the comparison was based in a pool of 11 normal oral 
tissues, whereas the spontaneously immortalized, but not transformed epithelial cell line HGK was used as reference for the comparison 
with OSCC-derived cell lines. The amounts of fascin (p<0.01; A) and plectin (p<0.05; C) mRNA were significantly higher in OSCC 
specimens than in the normal oral mucosa. The mRNA levels of fascin (B) and plectin (D) were also significantly higher in OSCC cell lines 
compared to HGK cells. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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To confirm our findings, the expression levels of 
fascin were investigated in an independent set of OSCCs 
(cohort 2; details provided in materials and methods 
section). In agreement, univariate and multivariate 
survival analysis indicated that high levels of fascin were 
significantly associated with poor prognosis (p<0.05; 
Supplementary Figure 3). Collectively, these findings 
suggest that the expression level of fascin could be used 
as an independent factor to predict poor prognosis of 
OSCCs.
Fascin knockdown suppresses the migratory and 
invasive potential of OSCC cells
To examine the role of fascin in OSCC progression, 
fascin knockdown was achieved in the aggressive and 
highly invasive cell line HSC-3 and in the less invasive 
SCC-15, by lentivirus-mediated shRNA expression. 
Both cell lines have high levels of fascin expression. 
As expected, cells transduced with lentivirus carrying 
a specific sequence targeted to the fascin transcript 
demonstrated a significant reduction in both fascin mRNA 
and protein levels in comparison with parental cells or 
cells transduced with the control, non-targeting sequence 
(Figure 5).
Knockdown of fascin did not impair the viability or 
proliferation potential of the cells (Figure 6), but resulted 
in a significant increase in cell adhesion on surfaces coated 
with fibronectin for both SCC-15 (p<0.05) and HSC-
3 cells (p<0.0001; Figure 7A). Transwell migration and 
invasion assays revealed that downregulation of fascin 
significantly inhibited the migratory (p<0.0001; Figure 
Figure 3: Fascin but not plectin is overexpressed in oral dysplasias. (A) Immunodetection of fascin and plectin in representative 
samples of oral fibrous hyperplasia, characterizing normal oral epithelium, oral dysplasia and OSCCs. The expressions of fascin and plectin 
were not restricted to the lower layers of the epithelium in the oral dysplasias. (B) As expected, the levels of fascin were significantly higher 
in OSCCs than in fibrous hyperplasia (p<0.0001). Fascin was also significantly upregulated in the OSCCs when compared with dysplasia 
samples, independently of the grade (p<0.001). In addition, fascin protein levels were significantly higher in dysplasias than in nontumor 
tissues (p<0.001). (C) The levels of plectin were significantly higher in OSCCs than in fibrous hyperplasias and dysplasias (p<0.0001), but 
no differences between fibrous hyperplasia and dysplasias were observed. 
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Correlation coefficient / p value Correlation coefficient / p value
Age 0.082 / 0.39 0.171 / 0.07
Gender -0.011 / 0.90 0.143 / 0.13
Smoking habit -0.080 / 0.45 0.005 / 0.96
Drinking habit 0.088 / 0.43 0.001 / 0.99
Tumor site 0.083 / 0.38 -0.059 / 0.53
T stage 0.051 / 0.60 -0.113 / 0.23
N stage 0.135 / 0.16 -0.063 / 0.51
Treatment 0.092 / 0.33 -0.021 / 0.82
Histopathological grade 0.158 / 0.09 0.138 / 0.15
Margin Status -0.101 / 0.29 0.194 / 0.04
Local recurrence 0.155 / 0.10 0.003 / 0.69
Regional recurrence 0.018 / 0.85 -0.031 / 0.74
Distant recurrence -0.003 / 0.96 0.134 / 0.16
Second primary -0.122 / 0.20 0.016 / 0.86
Figure 4: Kaplan-Meier cumulative curves for disease-specific and disease-free survivals of patients with OSCC according to expression 
of fascin (A and B) and plectin (C and D). Patients with high fascin expression corresponded to those with a significantly poorer outcome 
in disease-specific survival.
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Table 2: Cox multivariate analysis for the risk of death
Parameter
Disease-specific survival Disease-free survival
HR (95% CI) p value HR (95% CI) p value
Age
≤ 56 Reference
> 56 2.43 (1.24±4.76) 0.01
T stage
T1/T2 Reference Reference
T3/T4 2.31 (1.41±5.89) 0.003 2.05 (1.46-7.91) 0.04
N stage
N0 Reference
N+ 2.11 (1.20±4.30) 0.01
Fascin levels
Low Reference
High 2.86 (1.34±6.12) 0.007
Table 3: Cox regression analysis for disease specific and disease-free survival for combination of fascin levels and 
age, T stage and N stage in the 113 oral squamous cell carcinoma patients
Parameters
Disease specific survival Disease-free survival
Hazard ratio (95% CI) / p value Hazard ratio (95% CI) / p value
Univariate Multivariate Univariate Multivariate
Fascin and Age
Low fascin and < 56 Reference Reference
High fascin or ≥ 56 1.88 (1.09-3.25) / 0.04 1.58 (0.78-3.20) / 0.24
Fascin and T stage
Low fascin and T1/T2 Reference Reference Reference Reference
High fascin or T3/T4 3.45 (2.06-5.77) / <0.0001 4.82 (2.10-11.06) / 0.0002 2.07 (1.08-3.99) / 0.03 4.17 (1.39-12.43)/0.01
Fascin and N stage
Low fascin and N0 Reference Reference Reference
High fascin or N+ 2.90 (1.69-4.98) / 0.002 4.89 (1.87-12.79) / 0.001 1.49 (0.75-2.94) / 0.27
7B) and invasive (p<0.0001; Figure 7D) ability of SCC-
15 and HSC-3 cells. To further characterize the effects of 
fascin on migration and invasion, we carried out a scratch 
wound migration assay and a myoma organotypic invasion 
assay, respectively. As shown in Figure 7C, fascin-silenced 
cells (both SCC-15 and HSC-3) closed the scratch wound 
significantly more slowly than control cells (p<0.0001). 
Figure 8A illustrates the assessment of the invasive 
potential of the SCC-15 and HSC-3 cells in the myoma 
organotypic invasion assay. Invasion depth (Figure 
8B) and invasion area (Figure 8C) were significantly 
reduced in both SCC-15 and HSC-3 expressing shRNA 
targeting FSCN compared with parental and control 
shRNA cells grown in the myoma discs (p<0.0001). To 
determine whether fascin influences EMT, we examined 
the expression levels of the epithelial marker E-cadherin 
and of the mesenchymal marker vimentin in the fascin-
silenced cells. As indicated in Figure 7E, SCC-15 
expressing FSCN-targeting shRNA had high mRNA 
levels of E-cadherin and reduced expression of vimentin 
compared to shRNA-control expressing cells, while HSC-
3 cells expressing FSCN-targeting shRNA had reduced 
expression of vimentin, but had no significant increase on 
E-cadherin levels compared to shRNA-control expressing 
cells. Taken together, these results suggest that fascin is 
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Figure 5: Fascin knockdown efficiency in SCC-15 and HSC-3 cells. Cells were transduced with lentivirus expressing 
shRNA sequences against fascin (shRNA FSCN cells) and control (shRNA Control cells) as outlined in the methods. 
shRNA FSCN cells showed a marked reduction in both mRNA and protein levels when compared with parental cell and shRNA Control 
cells.
important for the migratory and invasive properties of 
OSCC cells.
Xenograft tumors from the HSC-3 shRNA FSCN 
cells in nude mice
Next, we assessed the potential action of fascin in 
tumorigenicity using HSC-3 xenograft tumors formed 
in the flank of BALB/c nude mice. The volume of the 
HSC-3 shRNA FSCN xenograft tumors was slightly 
decreased compared with tumors formed by the HSC-
3 shRNA Control cells (p<0.01, Figure 9A). No 
macroscopic or microscopic differences were observed, 
but the immunohistochemical analysis confirmed fascin 
knockdown in the HSC-3 shRNA FSCN xenograft 
tumor cells in contrast with high expression levels in the 
HSC-3 shRNA Control tumors (Supplementary Figure 
4). It is worth noting that some fascin immunostaining 
was detected on basal cells of tumor nests in HSC-3 
shRNA FSCN xenograft tumors. Three weeks after the 
implantation of the cells into the tongue of BALB/c 
nude mice, all animals exhibited tumors characterized 
by a firm mass in the middle part of the tongue. 
Visible cervical lymph nodes were carefully removed 
and investigated for the presence of metastasis using 
immunohistochemistry for pan-cytokeratins. The 
frequency of lymph node metastases was lower in HSC-
3 shRNA FSCN orthotopic tumors compared with HSC-3 
shRNA Control tumors, but did not reach a statistically 
significant level (p=0.18, Figure 9B). As expected, the 
tongue tumors formed by HSC-3 shRNA FSCN cells 
showed no immunoexpression of fascin (Supplementary 
Figure 4).
Downregulation of fascin ablates filopodia 
formation and reduces expression and 
phosphorylation of paxillin
Since fascin is associated with the initiation 
and formation of filopodia structures, we considered 
whether fascin-silencing in HSC-3 cells may affect 
filopodia formation. As expected, fascin-depleted cells 
demonstrated significantly lower number of filopodia 
in comparison with control clones (p<0.0001, Figure 
10A and Supplementary Figure 5). Subsequently we 
assessed whether fascin silencing could interfere in 
the expression of other proteins related to filopodia 
protrusions, including paxillin, vinculin and FAK. Fascin 
depletion was accompanied by a marked downregulation 
of paxillin, whereas no significant effects on vinculin 
and FAK expression could be observed (Figure 10B). 
Accordingly, fascin co-localized with paxillin in HSC-3 
shRNA Control cells and both fascin and paxillin were 
downregulated in HSC-3 shRNA FSCN cells (Figure 
10C). The fascin silenced cells stimulated with 50 ng/ml 
of EGF showed slight attenuation on paxillin and FAK 
phosphorylations in comparison with control (Figure 
10D). These results suggest that fascin may have an 
important role in filopodia development.
Fascin expression is inversely correlated with 
miR-138 in OSCCs
To gain insight into the molecular mechanism by 
which fascin is overexpressed in OSCCs, we determined 
the relationship between fascin mRNA levels and the 
expression of miR-138 and miR-145 in a series of OSCC 
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Figure 6: Downregulation of fascin does not affect viability or proliferation of SCC-15 and HSC-3 cells. Cells were 
subjected to MTS-cell viability (A and B) and bromodeoxyuridine (BrdU)-labeling cell proliferation (C and D) assays.
Figure 7: Overexpression of fascin is associated with adhesion, migration, invasion and acquisition of EMT properties. 
(A) Downregulation of fascin significantly induced the adhesive properties of SCC-15 and HSC-3 cells to fibronectin, and of HSC-3 cells 
on uncoated surfaces. (B) Migration of SCC-15 and HSC-3 cells were significantly decreased by fascin-specific shRNA, as revealed by 
transwell migration assay. (C) Migration analysis based on scratch wound migration assay showed that fascin-silenced cells (SCC-15 
shRNA FSCN and HSC-3 shRNA FSCN) closed the scratch wound significantly more slowly than parental cells (SCC-15 and HSC-3) and 
shRNA Control cells. (D) Invasion of SCC-15 and HSC-3 cells was significantly inhibited after fascin knockdown. (E) Downregulation of 
fascin induced significantly the expression of E-cadherin while reducing vimentin expression in SCC-15 cells. For HSC-3 cells, reduction 
of vimentin expression reached significant levels, while that the induction of E-cadherin did not. *p<0.05, **p<0.01, ***p<0.0001.
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Figure 8: Fascin downregulation inhibits the invasion of SCC-15 and HSC-3 cells in the myoma organotypic invasion 
model. (A) The knockdown of fascin markedly reduced the invasion properties of SCC-15 and HSC-3 cells in the myoma organotypic 
model when compared with control cells. The invasion depth (B) and the invasion area (C) were significantly reduced for HSC-3 shRNA 
FSCN cells. *p<0.0001.
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Figure 9: The mass of the tumors and the frequency of cervical lymph node metastasis in xenograft tumors formed by 
HSC-3 shRNA Control and HSC-3 shRNA FSCN cells. (A) In the subcutaneous tumor model, HSC-3 shRNA FSCN tumors were 
significantly smaller than HSC-3 shRNA Control tumors. (B) In the orthotopic tongue model, no differences in the frequency of cervical 
lymph node metastasis were observed. *p<0.01.
Figure 10: Inhibition of filopodia formation by fascin knockdown. (A) Actin filaments were labeled with rodhamine phalloidin, 
and the number of filopodia structures was estimated with the aid of the Image J software. Fascin knockdown significantly reduced 
the number of filopodia (p<0.0001). (B) Western blot analysis of filopodia-related proteins. Fascin-silenced cells demonstrated reduced 
expression paxillin in comparison with control cells. No significant effects were observed in FAK and viculin. (C) Confocal analysis 
revealed the colocalization of fascin and paxillin, and confirmed the decreased expression of paxillin in fascin-silenced cells. (D) HSC-3 
shRNA Control and HCS-3 shRNA FSCN were cultured in presence of 50 ng/ml of EGF for 5, 15 and 30 min, and assessed by western 
blot with antibodies against phospho-fascin, phospho-paxillin and phospho-FAK. Values above bands represent the densitometric analysis. 
Reduction in phosphorylation of paxillin and FAK occurs upon fascin-silencing in HSC-3 cells. *p<0.0001.
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Figure 11: Fascin is target by miR-138. (A) Expression of fascin is inversely correlated with miR-138, but not with miR-145, in 
OSCC samples. (B) SCC-15 cells were exposed to miR-1 (scramble control) or miR-138 and miR-145 mimics. Levels of fascin mRNA and 
protein were clearly decreased in miR-138 transfectants, demonstrating that miR-138 regulates fascin mRNA levels. (C) Overexpression of 
miR-138 significantly inhibited the migration of SCC-15 (p<0.005) and HSC-3 (p<0.01) cells. *p<0.01, **p<0.005.
fresh tumor samples. Previous studies showed that miR-
138 is downregulated in OSCCs [19, 20] and in silico 
target analysis revealed a conserved miR-138-binding 
site within 3' UTR of fascin mRNA (www.targetscan.
org). Similarly, previous studies revealed that miR-145 
regulates fascin expression in several different tumors 
[21, 22]. miR-138 showed a significant and inverse 
correlation with fascin levels (rho=-0.68 and p=0.04), 
whereas no correlation was observed for miR-145 
(Figure 11A). To determine whether miR-138 and miR-
145 regulate fascin mRNA, HSC-3 cells were transfected 
with miR-138 and miR-145 mimics. Heterologous over-
expression of miR-138, but not miR-145, resulted in 
a concomitant decrease in fascin mRNA and protein, 
suggesting that miR-138 has the capacity to regulate 
fascin expression in OSCC (Figure 11B). As expected, 
miR-145 overexpression clearly decreased activin A 
expression [23], confirming the efficiency of transfection 
(data not shown).
To explore the role of miR-138, we examined the 
effect of miR–138 in OSCC cell migration. As shown 
in Figure 11C, overexpression of miR-138 significantly 
decreased cell mobility compared with control in both 
SCC-15 (p=0.005) and HSC-3 (p=0.01). Therefore, 
these results indicated that miR-138 plays a crucial role 
in regulating the migration of OSCC cells via targeting 
fascin.
DISCUSSION
Prognostic indicators are important to refine 
treatment and forecasting outcomes in patients with 
OSCC. The most predictive factors to define risk category 
in OSCCs are the clinical stage and histological grade [2–
5]. None of the molecular markers assessed has so far been 
able to provide sufficiently accurate information to benefit 
patients [24]. Identification of protein expression profiles 
is important for understanding the mechanisms of oral 
tumorigenesis, as they could facilitate the development 
of new tools for the prevention, diagnosis, treatment and 
prognosis of OSCCs. We recently applied a proteomic-
based approach to identify differentially expressed tumor 
proteins in microdissected OSCCs compared to normal 
oral mucosa, and identified 69 proteins upregulated in 
OSCC [18]. Herein we selected fascin and plectin, two of 
the most significant overexpressed proteins, for validation 
and further analysis. Both proteins are related to promotion 
of cytoskeletal dynamics, increased migratory and 
invasive capacity and thereby the potential for metastasis. 
The effects of fascin and plectin on OSCC biology are not 
completely defined.
In the present study we confirmed that fascin and 
plectin are significantly upregulated in OSCC compared 
with normal oral mucosa at gene expression and protein 
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levels in patient samples. Fascin and plectin were also 
overexpressed in OSCC-derived cell lines. Subsequent 
immunohistochemical analysis of specimens representing 
OSCC development revealed that fascin levels were 
already significantly upregulated in mild dysplasias, 
keeping higher levels throughout oral cancer progression, 
whereas plectin upregulation was detected only in 
cancer areas. Further analysis showed that increased 
expression of fascin was significantly associated with 
shortened disease-specific survival for OSCC patients. 
Unexpectedly, plectin levels did not show statistical 
significance for survival in OSCC patients. In the 
multivariate Cox regression analyses, fascin emerged as an 
independent predictor factor of disease-specific survival 
along with consistent prognostic factors for OSCCs such 
as advanced age, tumors with high T classification and 
presence of cervical lymph metastasis (N stage) [25–27]. 
In the validation cohort (cohort 2), high levels of fascin 
were also significantly associated with worse prognosis, 
confirming fascin as a predictor of OSCC prognosis.
Earlier investigations also showed that fascin 
expression was increased in several types of cancer, 
including OSCC [12, 28], and the overexpression was 
an indicator of worse prognosis [12, 13]. Chen and 
collaborators [28] showed that high levels of fascin were 
associated with TNM clinical stage, but they did not show 
survival analysis. These authors mixed cancer located 
at oral and oropharyngeal sub-sites, which are proofed 
to be distinct regarding etiology and prognosis. The 
immunoexpression of fascin was significantly higher in 
dysplasia and in situ carcinoma than in benign diseases 
[29], reinforcing our findings that fascin can be helpful for 
improving the diagnostic accuracy of dysplasias that will 
progress to oral carcinoma. Two studies evaluated plectin 
as a prognostic marker in head and neck carcinomas, 
however, they presented results opposed to ours [17, 30]. 
Patients with higher levels of plectin showed a lower 
overall survival rate, which was probably related with the 
higher metastatic potential of the tumors with increased 
plectin level [17]. Nevertheless, these authors included 
tumors from different sites (oropharynx, hypopharynx, 
larynx and salivary glands), raising the question if 
the significance was not driven by tumor from sites 
different than oral cavity (site-dependency). Rikardsen 
and collaborators [30] found high expression of plectin 
correlated significantly with disease-specific-survival in all 
patients with non-metastatic disease.
Previous studies have shown that fascin, as an actin-
binding and bundling protein, promotes cell migration 
and adhesion dynamics in vitro and tumor metastasis in 
vivo. Furthermore, fascin can directly interact with the 
microtubule cytoskeleton, which does not depend upon 
fascin-actin bundling, further contributing to regulation of 
focal adhesion dynamics and cell migration speed [31]. 
We generated OSCC cell lines stably expressing shRNA 
targeting fascin to understand the exact role of fascin 
in preclinical model. In agreement with other studies, 
fascin knockdown had no significant effects on viability 
and proliferative potential of OSCC cells [32, 33]. In 
contrast, overexpression of fascin increased proliferation 
of OSCC cells, which was accompanied by upregulation 
of PI3K and MAPK pathways [13]. The cell proliferation 
differences suggest that fascin may have distinct roles 
in the context of cell tumor origin. In accordance with 
previous studies [12–14], we also demonstrated that 
fascin plays a negative control on cell adhesion and 
regulate migration and invasion status of OSCC cells, 
which may explain why higher fascin expression was 
significantly correlated with worse prognosis. High fascin 
expression induced hepatocellular carcinoma cell invasion 
associated with loss of E-cadherin and gain of matrix 
metalloproteinases 2 and 9 levels [34]. EMT comprise 
the biological processes by which cells transit between 
epithelial and mesenchymal states and includes decreased 
cell-cell adhesion and increased cell motility and 
metastasis [35]. In cells depleted of fascin, we observed 
an induction of E-cadherin and a repression of vimentin, 
suggesting that overexpression of fascin promotes the 
EMT, an important phenotype for invasion and metastasis. 
The xenograft tumors in the flank were slighted smaller 
in the presence of fascin-silenced OSCC cells, but the 
orthotopic model showed no differences in the frequency 
of cervical lymph node metastasis between tumors formed 
by cells knockdown for fascin and their controls. This 
finding can be attributed to the high aggressive behavior of 
the OSCC cells (specifically HSC-3), since silencing the 
gene expression of fascin was not able to reduce the highly 
metastatic potential of this cell line. To provide a better 
understanding of the molecular events involved in the 
fascin-mediated OSCC progression is necessary additional 
in vivo experiments and mechanistic studies.
In the context of cell migration, the transport of 
adhesion proteins and receptors to filopodia tips has been 
implicated in the formation and reinforcement of cell-cell 
junctions [36, 37], contributing to cell locomotion [38]. 
Villari and collaborators [31] demonstrated that fascin 
may interact directly with the microtubule cytoskeleton 
independently of actin cooperation, to generate a complex 
with FAK and Src to control adhesion stability. Evidences 
demonstrated that filopodia shaft adhesions can mature 
into focal adhesions upon lamellipodia advancement [39], 
suggesting that focal adhesion proteins found at the shaft 
and/or tip of filopodia could be representative of nascent 
adhesions. Our results revealed reduced expression of 
paxillin and decreased phosphorylation of both paxillin 
and FAK following EGF stimuli in fascin-silenced cells. 
These findings support that fascin has a direct effect on 
filopodia organization in the context of focal adhesion 
formation during the invasion process.
Another interesting finding of the present study lies 
on the microRNA analyses. Our findings revealed that the 
expression of miR-138 is inversely correlated with fascin 
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levels, and the transfection of miR-138 mimic in OSCC 
cells result in a downregulation of fascin, suggesting 
that fascin overexpression in OSCCs is, at least in part, 
regulated by this microRNA. On the other hand, no 
correlation between miR-145 and fascin transcripts was 
observed and ectopic expression of miR-145 did not alter 
significantly fascin at both mRNA and protein levels. miR-
138 is frequently down-regulated in various tumors [19, 
20, 40] and its reduced expression is associated with a 
shorter tumor-specific and relapse-free survival [41, 42]. 
It has been described that miR-138 has tumor suppressive 
functions, including regulation of proliferation, apoptosis, 
migration and invasion. In non-small-cell lung cancer, 
forced expression of miR-138 inhibited cell proliferation 
and reversed epithelial-mesenchymal transition via target 
of G-protein-coupled receptor kinase-interacting protein 
1 and semaphorin 4C [43], and up-regulation of miR-138 
inhibited hypoxia-induced cardiomyocyte apoptosis via 
down-regulating lipocalin-2 expression [44]. A previous 
study showed that miR-138 expression is involved in the 
multidrug resistance of leukemia cells through down-
regulation of MDR1 [45]. However, a following study 
revealed that miR-138 modulates MDR1 expression 
indirectly by inhibiting NF-κB/p65, a well known 
transcriptional factor involved in MDR1 regulation [46]. 
Importantly, the multidrug resistance of human leukemia 
cell line HL-60 was achieved after overexpression of 
miR-138. Thus, loss of miR-138, which is an endogenous 
inhibitor of fascin, may promote aberrant expression of 
fascin and other targets, contributing to pathogenesis and 
progression of OSCCs.
In conclusion, fascin is upregulated in patients with 
OSCC and OSCC-derived cell lines, the overexpression of 
fascin is significantly correlated with disease progression 
and poor outcome, and fascin may have a major role 
in OSCC migration and invasiveness process. Further 
investigation is necessary to establish fascin as a routine 
therapeutic target for patients with OSCC.
MATERIALS AND METHODS
Tissue samples
The study was approved by the Human Research 
Ethics Committee of the School of Dentistry, University 
of Campinas (protocol number: 090/2011). This study 
included different sets of human samples. Initially, to 
confirm the higher expression of fascin and plectin in 
OSCC samples compared with healthy oral mucosa, we 
performed immunohistochemical analysis in the ten pairs 
of samples used in the original LC-MS/MS screening [18]. 
To expand the number of samples and characterize further 
the expression pattern of fascin and plectin, fresh samples 
of OSCC (n=11) and normal oral mucosa (n=11) were 
used to investigate the expression of fascin and plectin 
using real time quantitative PCR (qPCR) [47]. Those 
samples were also used for the expression of miR-138 and 
miR-145, putative microRNA regulators of fascin mRNA.
Immunohistochemical analysis was also performed 
in two independent sets of samples characterizing OSCC 
development. Cohort 1 was composed by 29 cases of 
oral fibrous hyperplasias with normal epithelium, 24 
mild epithelial dysplasia, 26 moderate dysplasia, 19 
severe dysplasia and 113 primary OSCCs. Oral epithelial 
dysplasias and OSCCs were classified according to the 
World Health Organization (WHO) grading system. 
Clinicopathological features of these 113 OSCC patients 
who were diagnosed and treated from 1998 to 2008 at 
Oncology Center of Cascavel (CEONC, n=46 patients) 
and UOPECCAN Cancer Hospital (n=67 patients) were 
described [5]. Cohort 2 was composed by 52 primary 
OSCCs diagnosed and treated at Jewish General Hospital, 
McGill University [48]. The samples were contained in 
a tissue microarray (TMA) and were used to validate the 
fascin findings.
Cell cultures
Normal human gingival keratinocyte cell line 
(HGK) was cultured in serum-free, low calcium media 
(Gibco’s Keratinocyte-SFM; Invitrogen, USA) containing 
specific supplements and antibiotics [49]. The human 
OSCC cell lines SCC-4, SCC-9, SCC-15 and SCC-25 were 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA), and cultured as recommended 
in a 1:1 mixture of Dulbecco’s modified Eagle’s media 
and Ham’s F12 media (DMEM/F12; Invitrogen, USA) 
supplemented with 10% fetal bovine serum (FBS), 400 ng/
ml hydrocortisone (Sigma-Aldrich, USA) and antibiotics. 
The SCC-9 ZsGreen LN-1 cell line, isolated from a 
metastatic cervical lymph node, was previously described 
[50], and cultured in the same conditions as the parental 
SCC-9 cell line. HSC-3, a human tongue squamous cell 
carcinoma cell line (JCRB 0623; Osaka National Institute 
of Health Sciences, Japan), was cultured in DMEM/F-12 
media (Invitrogen, USA) supplemented with 10% FBS, 
50 μg/ml ascorbic acid (Sigma-Aldrich, USA), 400 ng/
ml hydrocortisone (Sigma-Aldrich, USA) and antibiotics. 
All cells were growth at 37°C in a humidified atmosphere 
of 5% CO2.
Immunohistochemistry
Immunostaining of fascin and plectin was 
performed using the streptavidin-biotin peroxidase 
complex method. Briefly, after dewaxing and hydration 
in graded alcohol solutions, the sections were treated 
with 3% H2O2 followed by antigen retrieval with 10 mM 
citric acid pH 6.0 in a pressure cooker. After washing 
with phosphate-buffered saline (PBS), the sections 
were treated with 1% bovine serum albumin (BSA) 
in PBS for 1 h and then incubated with monoclonal 
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mouse antibody against fascin (clone IM20; Abcam 
Inc, USA), diluted 1:700, or polyclonal goat antibody 
against plectin (clone C-20; Santa Cruz Biotechnology 
Inc, USA), diluted 1:200, followed by the LSAB method 
(LSAB+ System-HRP kit, Dako, USA). Reactions 
were developed by incubating the sections with 0.6 
mg/ml 3,3'-diaminobenzidine tetrahydrochloride 
(Sigma-Aldrich, USA) containing 0.01% H2O2. Control 
reactions were performed by omission of the primary 
antibody (Supplementary Figure 6). Immunoexpression 
was assessed with the aid of the Aperio ScanScope CS 
(Aperio Technologies, USA), as previously described 
[23].
The TMA immunostaining (OSCC cohort 2) was 
performed in the Nexus Immunostainer (Ventana Medical 
Systems, USA) using antibodies against fascin (1:100, 
clone 55K2; Santa Cruz Biotechnology, USA). Each core 
was scanned and protein expression was assessed using 
a four-tiered system as previously described [48]. For 
statistical analysis, samples were categorized into two 
groups: negative/weak (low expression) and moderate/
strong (high expression).
qPCR
Total RNA from fresh tissues and cell lines was 
isolated with the RNeasy mini kit (Qiagen, USA) 
according to the manufacturer's protocols. Following 
DNase I treatment in order to eliminate genomic DNA 
contamination, 1 μg of total RNA per sample was used 
to generate cDNA using Oligo-dT (Invitrogen, USA) 
and reverse transcriptase (Superscript II RT enzyme, 
Invitrogen, USA). The resulting cDNAs were subjected 
to qPCR using specific primers and SYBR® Green 
PCR master mix (Applied Biosystems, USA) in the 
StepOnePlus Real Time PCR (Applied Biosystems, 
USA). Gene expression was determined using the 2-ΔΔCt 
method and the housekeeping gene PPIA (cyclophilin 
A) was used as reference gene for data normalization. 
All reactions were performed in triplicate. The primers 
used in this study are as follows: FSCN1 (fascin) 
forward 5’GGCGAGTCTGGCACCTCTT3’ and reverse 
5’CCCCAACCGTCCCTTAGC3’, PLEC (plectin) 
forward 5’GGAGGATGCGTTTCCACAA3’ and reverse 
5’ATATCTGAGATCTGGAAGTGCAGAA3’, and PPIA 
forward 5’GCTTTGGGTCCAGGAATGG3’ and reverse 
5’GTTGTCCACAGTCAGCAATGGT3’.
Stable cells mediating fascin silence
Lentiviral vectors containing short hairpin RNA 
(shRNA) targeting human fascin (FSCN1 MISSION® 
shRNA Lentiviral Transduction Particles-SHCLNV-
NM_003088) or scrambled control shRNA (MISSION® 
pLKO.1-puro Non-Mammalian shRNA Control) were 
prepared by Sigma-Aldrich (USA). SCC-15 and HSC-3 
cells grown in a 12-well plate at confluence of 70% were 
incubated with control or fascin shRNA lentiviral particles 
at a multiplicity of infection (MOI) of 1.5 in culture media 
containing 8 mg/ml of polybrene (Sigma-Aldrich, USA) 
for 4 h. After washing with PBS, cells were cultured in 
fresh media for an additional period of 48 h. Cells were 
then cultured for 10 days in the presence of 1 μg/ml of 
puromycin dihydrochloride (Sigma-Aldrich, USA) to 
select resistant cells. The efficacy of fascin knockdown 
was determined by qPCR and western blot.
Western blot analysis
Cells were washed with cold PBS and lysed in a 
protein-lysis buffer containing 10% sucrose, 1% NP-40, 
20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 
2 mM EDTA and a cocktail of protease inhibitors 
(Roche Diagnosis, USA). After centrifugation, protein 
concentrations were measured using a protein assay 
according to the manufacturer’s instructions (Bio-Rad 
Protein Assay, Bio-Rad, USA). Thirty μg of total protein 
per sample were resolved in a 10% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing conditions, and transferred to nitrocellulose 
membranes. The membranes were blocked with 10% non-
fat dry milk in PBS containing 0.1% Tween-20, rinsed in 
the same buffer, and incubated for 2 h with monoclonal 
mouse antibody against fascin at 1:1,000 (clone IM20; 
Abcam Inc, USA) or monoclonal mouse antibody against 
β-actin (clone AC-15; Sigma-Aldrich, USA) at 1:50,000. 
After washing, the membranes were incubated with anti-
mouse IgG fluorescein-conjugated (Cell Signaling, USA), 
and signals captured with an Alliance 9.7 instrument 
(UVITEC, Cambridge, UK).
Cell viability and cell proliferation assays
Cell viability and cell proliferation assays were 
performed according to Sobral [51]. Three independent 
experiments were performed with five replicates.
Adhesion assay
Adhesion analysis was performed as described 
previously [52], using fibronectin (BD Biosciences, USA) 
or myogel [53] as substrate.
Migration and invasion assays
The migratory potential of the fascin silenced-
cells was assessed by both transwell migration assay and 
scratch wound migration assay (IncuCyte™ live-cell 
imaging system - Essen BioSciences), whereas invasion 
assays were based in the transwell with myogel solidified 
with low-melting agarose [53] and in the human myoma 
organotypic culture [54].
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Analysis of EMT markers E-cadherin and 
vimentin
The expression of the epithelial marker E-cadherin 
and of mesenchymal marker vimentin was carried out 
using qPCR as previously described [47].
Quantification of filopodia
HSC-3 shRNA FSCN and HSC-3 shRNA control 
cells were fixed in 1% paraformaldehyde in PBS 
containing 0.25% Triton X-100 for 15 min, and then 
were incubated with rhodamine phalloidin (diluted 1:100; 
Invitrogen, USA) for 1 h. Quantification of filopodia 
was performed with images captured with a fluorescent 
microscope (Axiophot; Carl Zeiss MicroImaging Inc, 
Germany).
Analysis of filopodia-related proteins
Paxillin, focal adhesion kinase (FAK) and 
vinculin expression in fascin-silenced HSC-3 cells 
and controls was assessed by western blot, using the 
following antibodies: anti-paxillin (diluted 1:500; 
Abcam Inc, USA), anti-phospho paxillin (diluted 
1:500; Cell Signaling, USA), anti-FAK (diluted 1:500; 
Millipore, USA), anti-phospho-FAK (diluted 1:500; 
Cell Signalling, USA), anti-vinculin (diluted 1:500; 
Sigma-Aldrich, USA), anti-GAPDH (diluted 1:500; 
Sigma-Aldrich, USA). Western blot with phospho-fascin 
(1:50, clone FP2661; ECM Bioscience, USA) was also 
performed.
To assess the effects of epidermal growth factor 
(EGF) stimuli on paxillin and FAK phosphorylation, 
HSC-3 shRNA Control and HCS-3 shRNA FSCN cells 
were starved and cultured for 5, 15 and 30 min with media 
containing 50 ng/ml of EGF (Sigma-Aldrich, USA).
Confocal microscopy
HSC-3 cells grown on glass coverslips for 24 h 
were fixed in 1% paraformaldehyde in PBS containing 
0.25% Triton X-100 for 15 min. The cells were then 
washed twice with PBS and blocked with blocking 
buffer (1% BSA and 2% normal goat serum in PBS) for 
30 min. Antibodies targeting fascin (clone 55K2; Santa 
Cruz Biotechnology, USA), diluted 1:500, and paxillin 
(Abcam Inc, USA), diluted 1:100, were added. The cells 
were washed 3 times in PBS and incubated in blocking 
buffer containing respective Alexa-conjugated secondary 
antibodies (Invitrogen, USA) at 1:1000 and incubated 
for 1 h at room temperature. Cells were mounted with 
Vectashield containing DAPI (Vector Labs, USA). 
Images were captured using a 40x or 60x oil immersion 
objectives on the Wave FX spinning disk confocal 
microscopy system (Quorum Technologies) and analyzed 
using Volocity.
Tumorigenicity assay
To assess the growth of xenograft tumors in 
nude mice, HSC-3 shRNA Control and HSC-3 shRNA 
FSCN were injected subcutaneously in the flank or 
were implanted into the tongue (orthotopic model) of 
12 week-old BALB/c nude mice (20 animals/cell line). 
Animals were sacrificed 3 weeks later and the tumors 
in the dorsum were dissected, weighted and fixed in 
10% formalin for hematoxylin and eosin (HE) stain 
and immunohistochemistry. Animals, which received 
the injection of the tumor cells in the tongue, had the 
tongue and cervical lymph nodes dissected, fixed and 
subjected to HE stain and immunohistochemistry. 
Primary tumors (both in flank and tongue) were subjected 
to immunohistochemical analysis using the anti-fascin 
antibody, whereas cervical lymph nodes were analyzed 
with anti-pancytokeratin (clone AE1/AE3; Dako, USA).
Correlation between fascin and miR-138 and 
miR-145 expression
The expression of miR-138 and miR-145 was 
assessed in fresh tumor specimens. Briefly, 1 μg of 
total RNA was converted into specific cDNA derived 
from mature microRNAs using TaqMan microRNA 
Reverse Transcription Kit (Applied Biosystems, USA) 
and quantified in triplicate using the TaqMan microRNA 
assay. The small nucleolar RNA (snoRNA) RNU48 was 
used as endogenous control. All assays were obtained 
from Applied Biosystems through their Assay-on-
Demand service. Data were quantified and analyzed 
using sequence detection system (version 2.3) (Applied 
Biosystems, USA). The microRNA relative expression 
in fresh tumor specimens was normalized against 
endogenous control and pooled normal oral mucosa 
samples.
Effect of miR-138 and miR-145 mimics on fascin 
expression
HSC-3 cells were transfected with miR-138 or miR-
145 mimics using the RNAiMAX reagent (Invitrogen, 
USA) as per the manufacturer's instructions. As control, 
cells were transfected with an unspecific scramble 
sequence (Pre-miR Negative Control #1-miR-1, Life 
Technologies, USA). After 72 h, cells were harvested and 
subjected to qPCR and western blot for quantification of 
fascin as described above.
Statistical analysis
Differences on expression of fascin and plectin 
between OSCC and normal oral mucosa samples were 
analyzed using the Mann-Whitney U test. To assess the 
immunohistochemical expression of fascin and plectin 
in the set of samples characterizing OSCC progression, 
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Kruskal-Wallis test was applied. Correlations between 
immunohistochemical expression of fascin and plectin 
and clinicopathological parameters of the tumors were 
performed using Spearman’s rank correlation. Survival 
curves were constructed based on the Kaplan-Meier 
method and compared with the Log-rank test. For 
multivariate survival analysis, the Cox proportional hazard 
model with a stepwise method including all parameters 
was employed.
All in vitro assays were performed at least three 
times. Mann-Whitney U test or one-way analysis of 
variance (ANOVA) with post-hoc comparisons based on 
the Tukey's multiple comparisons test were applied. The 
level of significance considered was 5% (p≤0.05).
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